Rituximab
- PDF / 141,410 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 60 Downloads / 157 Views
1
S
Neutropenia: 3 case reports A retrospective study identified three patients who developed neutropenia during treatment with rituximab 375 mg/m2 infused on days 1 and 10 of each cycle, given in combination with ifosfamide, etoposide and high dose cytarabine (IVAC) and/or cyclophosphamide, doxorubicin, vincristine, and methotrexate (CODOX-M) chemotherapy for non-Hodgkin’s lymphoma. Two men, aged 60 years and 49 years, developed grade 3 transient neutropenia 3 months and 6 months, respectively, following their last cycle of treatment. Their neutropenia, which lasted 10–14 days, was self-limiting and did not require treatment. A 58-year-old woman failed to regenerate blood counts over a 30-day period following her last cycle of IVAC. Additionally, she developed an invasive fungal infection [time to reaction onset and patient outcome not clearly stated]. Author comment: In patients 1 and 2 "the case was attributed to delayed rituximab-related neutropenia," and in the third patient "a contributory rituximab effect could not be excluded." Mohamedbhai SG, et al. Rituximab in combination with CODOX-M/IVAC: A retrospective analysis of 23 cases of non-HIV related B-cell non-Hodgkin lymphoma with proliferation index >95%. British Journal of Haematology 152: 175-181, No. 2, Jan 2011. Available from: URL: http://dx.doi.org/10.1111/ 803048678 j.1365-2141.2010.08447.x - United Kingdom
0114-9954/10/1336-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
Reactions 29 Jan 2011 No. 1336
Data Loading...
